In OCC 2026 Quest for Truth roundtable, leading cardiovascular experts from China and Australia gather to discuss “Hypertension · Cornerstone Chapter — From Blood Pressure Management to Root-Cause Innovation”. The session is hosted by Prof. Gang Wu, Shanghai General Hospital, and co-hosted by Prof. Dongying Zhang, The First Affiliated Hospital of Chongqing Medical University. Quest for Truth is honored to welcome two distinguished guest speakers: Prof. Xiangqing Kong, The First Affiliated Hospital with Nanjing Medical University; and Prof. Alberto P. Avolio, Macquarie University, Australia.
The roundtable focuses on how hypertension care may evolve from numerical blood pressure control toward mechanism-based and precision-oriented management. The experts discuss the limitations of lifelong medication, the low global control rate of hypertension, central nervous system regulation, perirenal adipose tissue as a potential therapeutic target, arterial stiffness and hemodynamic mechanisms, cuffless and wearable blood pressure monitoring, clinical validation standards, and the future role of Chinese innovation in reshaping global hypertension treatment.
In this segment, Prof. Alberto P. Avolio discusses what may matter most for the next generation of hypertension care in China. Responding to whether smart monitoring, precision drugs, or innovative devices should take priority, he emphasizes that all of these approaches are important and must work together to improve patient health.
Prof. Avolio highlights the need for reliable measurement, strong basic science, validated procedures, and trustworthy data systems. While population-based guidelines remain essential for saving lives, he notes that hypertension care is moving toward personalization, where AI, labeled data, and clinical trust will be critical to helping doctors make the right decision for each patient.